Risks for Anaphylaxis Compared Among IV Iron Products
Rates of anaphylaxis low for IV iron products, but risk for anaphylaxis increased with iron dextran and ferumoxytol compared with iron sucrose (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 29, 2022 Category: Cancer & Oncology Tags: Family Medicine, Internal Medicine, Allergy, Emergency Medicine, Nursing, Oncology, Pharmacy, Journal, Source Type: news
Risks for Anaphylaxis Compared Among IV Iron Products
TUESDAY, March 29, 2022 -- The rates of anaphylaxis are low for commonly used intravenous (IV) iron products, but the risk for anaphylaxis is increased for iron dextran and ferumoxytol compared with iron sucrose, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 29, 2022 Category: Pharmaceuticals Source Type: news
Pumping (IV) Iron Linked to Varying Anaphylaxis Risk for Older Adults
(MedPage Today) -- While the risk of anaphylaxis after administration of IV iron product was low among older adults, it was more common after certain iron products, researchers found.
The highest adjusted incidence rates for anaphylaxis among... (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - March 28, 2022 Category: Allergy & Immunology Source Type: news
New Data Show Majority of Adults with Moderate to Severe Plaque Psoriasis Treated with First-in-Class TREMFYA ® (guselkumab) Experienced Durable Skin Clearance Through Five Years Regardless of Metabolic Syndrome Status, Baseline Disease Severity, or Treatment History
SPRING HOUSE, PENNSYLVANIA, March 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced its first-in-class interleukin (IL)-23 inhibitor TREMFYA® (guselkumab) provided a consistent, high degree of durable skin clearance through five years in a majority of adult patients across broad subpopulations with moderate to severe plaque psoriasis (PsO) in the Phase 3 VOYAGE 1 and VOYAGE 2 clinical trials.1 A separate post hoc analysis of the VOYAGE studies showed TREMFYA provided high rates of efficacy and durability through five years and similar safety outcomes among patients with and without...
Source: Johnson and Johnson - March 25, 2022 Category: Pharmaceuticals Source Type: news
Childhood Cold Allergy Lingers and Raises Risk for Anaphylaxis Childhood Cold Allergy Lingers and Raises Risk for Anaphylaxis
Children with cold urticaria had an elevated risk for anaphylaxis, and resolution often took years, a study from Canada reports.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 18, 2022 Category: Consumer Health News Tags: Allergy & Clinical Immunology News Source Type: news
U.S. FDA Approves CARVYKTI ™ (ciltacabtagene autoleucel), Janssen’s First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., February 28, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has approved CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.1 The approval is based on data from the pivotal CARTITUDE-1 study, which included patients who had received a median of six prior treatment regimens (range, 3-18), and had previously rec...
Source: Johnson and Johnson - March 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
What Are Some Mast Cell Disorders?
Discussion
Mast cells (MCs) were first discovered by Paul Ehrlich in 1878. Previously in 1869, Nettleship and Tay described a toddler with chronic urticaria and a brown skin lesion which is believed to be the first reported case of mastocytosis. Urticaria pigmentosa was a term first used by Sangster in 1878, and in 1936 the term mastocytosis was used.
“Mast cells first evolved 500 million years ago in Ascidians (sea squirts), providing host innate immunity against bacteria and parasites….MCs gained additional functions regulating inflammation, wound healing, coagulation, adaptive immunity and acute allergic res...
Source: PediatricEducation.org - February 21, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
ARS Pharmaceuticals Expands Executive Leadership Team with Addition of Pharmaceutical Commercialization Veterans
SAN DIEGO, Feb. 9, 2022 -- (Healthcare Sales & Marketing Network) -- ARS Pharmaceuticals, Inc., a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead... Biopharmaceuticals, Personnel ARS Pharmaceuticals, intranasal epinephrine, anaphylaxis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 9, 2022 Category: Pharmaceuticals Source Type: news
Phase 1 Trial Shows Epinephrine Can Meet Therapeutic Thresholds When...
Treatment shows promise as a viable alternative for the treatment of anaphylaxis, according to new research from the 2022 AAAAI Annual Meeting.(PRWeb February 03, 2022)Read the full story at https://www.prweb.com/releases/phase_1_trial_shows_epinephrine_can_meet_therapeutic_thresholds_when_administered_sublingually/prweb18466094.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 3, 2022 Category: Pharmaceuticals Source Type: news
Clinical Controversies: Stop Playing Games with Anaphylaxis
No abstract available (Source: Emergency Medicine News)
Source: Emergency Medicine News - January 1, 2022 Category: Emergency Medicine Tags: Clinical Controversies Source Type: news
Post-It Pearls: Observing Biphasic Anaphylaxis Patients
No abstract available (Source: Emergency Medicine News)
Source: Emergency Medicine News - January 1, 2022 Category: Emergency Medicine Tags: Post-It Pearls Source Type: news
New Data from MajesTEC-1 Study Show Continued Deep and Durable Responses of Teclistamab (BCMAxCD3 Bispecific Antibody) in Treatment of Heavily Pretreated Patients with Multiple Myeloma
The objective responsive rate observed in this study suggests a potential benefit for many patients with triple-class exposed disease with an off-the-shelf therapy.”As of September 2021, 165 patients were treated with teclistamab at the SC 1.5 mg/kg dose across both Phase 1 and Phase 2 of MajesTEC-1.1 The primary objectives of the MajesTEC-1 Phase 1 study (NCT03145181) were to identify the recommended SC RP2D (part 1) and characterize the safety and tolerability of teclistamab at the RP2D (part 2). The primary objective of the MajesTEC-1 Phase 2 study (NCT04557098) was to evaluate the efficacy of teclistamab at the RP2D,...
Source: Johnson and Johnson - December 13, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Presents Updated Results Evaluating First-in-Class Talquetamab (GPRC5DxCD3 Bispecific Antibody) in Heavily Pretreated Patients with Multiple Myeloma
ATLANTA, Ga., December 11, 2021– The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the MonumenTAL-1 Phase 1 first-in-human dose-escalation study of talquetamab (NCT03399799). Talquetamab is the only investigational off-the-shelf T cell redirecting bispecific antibody in clinical development targeting both GPRC5D, a novel multiple myeloma target, and CD3 on T cells.[1] Results from the study show that no new safety signals were observed with longer follow-up.1 Heavily pretreated patients with multiple myeloma treated with talquetamab at the recommended subcutaneous (SC) Pha...
Source: Johnson and Johnson - December 11, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
New Clinical and Real-World Data Support Use of DARZALEX ® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma
ATLANTA, Ga., December 11, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new analyses illustrating responses that first-line treatment with DARZALEX® (daratumumab)-based regimens may be able to achieve, including a potential survival benefit for DARZALEX® in combination with lenalidomide and dexamethasone (Rd). Updated data from the randomized Phase 2 GRIFFIN study in transplant-eligible patients and real-world evidence in transplant-ineligible patients were presented at the American Society of Hematology (ASH) 2021 Annual Meeting. Data from the GRIFFIN study will also be featured...
Source: Johnson and Johnson - December 11, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Anaphylaxis to stinging insect venom - Adams KE, Tracy JM, Golden DBK.
Hymenoptera stinging insects are common culprits for allergic reactions. Anaphylaxis to insect stings can be life threatening and is associated with a significant risk of recurrence. Insect allergy requires referral to an allergist/immunologist for educati... (Source: SafetyLit)
Source: SafetyLit - November 29, 2021 Category: International Medicine & Public Health Tags: Non-Human Animals and Insects Source Type: news
